MSB Trading 2021 - paradigm shift, page-128

I first came across the issue in mid april last year, mentioned in this post

"There's that phrase again, Endothelial Dysfunction, in a Press Release 13 April, 2020

Mount Sinai Study Finds COVID-19 May Be Driven by Pulmonary Thrombi and Pulmonary Endothelial Dysfunction "

A couple of paras from the press release;

"“It seems that for at least a significant subset of these patients, the underlying driver of respiratory failure and organ dysfunction is actually thrombosis and endothelial dysfunction,” said Hooman Poor, MD, Assistant Professor of Medicine (Pulmonary, Critical Care and Sleep Medicine) at the Icahn School of Medicine at Mount Sinai. “Future clinical trials will need to evaluate the role of anticoagulation for milder disease and thrombolysis for more severe disease.”

The high prevalence of obesity, hypertension, and diabetes in patients with severe COVID-19 pneumonia may point to an underlying susceptibility to endothelial injury and dysregulation, in which the inner lining of the small arteries fails to perform all of its important functions. The researchers advise that these therapeutic approaches should be considered in the management of COVID-19 patients and must be further examined in clinical research studies."

A couple of days ago @col69 reported the news a heparin trial had been halted, that was aimed at controlling or eliminating the thrombosis;

"Trials Halt Full-Dose Clot Prophylaxis for Severe COVID-19"

"Preemptive therapeutic-level heparin appeared futile and possibly unsafe for COVID-19 patients in three large-scale international trials."

https://www.medpagetoday.com/infectiousdisease/covid19/90351

At least we know Revascor has a systemic effect on reducing endothelial dysfunction from both the LVAD trials. Will remestemcel-L do so in the case of COVID19, maybe we will begin to find out in the next month or so as the data is unblinded.